Zhejiang Hisun Pharmaceutical Co. Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Taizhou China (1956)

Organization Overview

First Clinical Trial
2013
NCT01998620
First Marketed Drug
2009
irinotecan (Camptosar)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

HISUN PHARM HANGZHOU | Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd | ZHEJIANG HISUN PHARM | Zhejiang Hisun Pharmaceutical Co. Ltd. | Zhejiang Hisun Pharmaceuticals Co., Ltd

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Arthritis (Phase 1)

Arthritis, Rheumatoid (Phase 1)

Breast Neoplasms (Phase 3)

Cholestasis (Phase 4)

Coronary Artery Disease (Phase 3)

Coronary Disease (Phase 3)

Esophageal Neoplasms (Phase 1)

Heart Diseases (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis, Alcoholic (Phase 4)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 4)

Hypercholesterolemia (Phase 3)

Infections (Phase 3)

Intraabdominal Infections (Phase 3)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Myocardial Ischemia (Phase 3)

Sepsis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial APIs: 23